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ABSTRACT 
Objective: The objective of this selective EBM review is to determine whether or not lifitegrast 
5.0% ophthalmic solution is effective in improving eye dryness and safe, in terms of ocular 
adverse effects, in adults 18 years or older with dry eye disease (DED). 
Study Design: Systematic review of three primary double-blinded, randomized placebo-
controlled trials that were published in peer-reviewed journals between 2014-2017. 
Data Sources: Studies were obtained through the PubMed database based on relevance to the 
clinical question and evaluation of patient-oriented outcomes.  
Outcomes Measured: Efficacy of lifitegrast treatment was measured based on the eye dryness 
score (EDS) obtained from a subject-reported symptom assessment using a 7-item visual analog 
scale. Safety of treatment was measured through investigator safety assessments and recording of 
adverse events conducted at study visits.  
Results: All three analyzed randomized control trials showed a greater reduction in the EDS 
with lifitegrast 5.0% ophthalmic solution compared to placebo. In Holland et al., the reduction in 
the EDS was 10.7% greater with lifitegrast compared to placebo (p=0.0007). In Sheppard et al., 
the reduction was 17.8% greater with lifitegrast (p=0.0291). In Tauber et al., lifitegrast showed a 
12.3% greater reduction (p<0.0001). For the safety assessment, lifitegrast had more ocular 
adverse effects (OAE) than placebo, with majority being mild to moderate in severity. In Holland 
et al., 39.5% who received lifitegrast had OAE in comparison to 17.8% who received placebo. In 
Sheppard et al., 33.7% with lifitegrast had OAE compared to 16.4% with placebo. In Tauber et 
al., 63.5% with lifitegrast had OAE compared to 26% with placebo. The NNH was 5 in Holland 
et al., 3 in Sheppard et al., and 6 in Tauber et al.  
Conclusions: Lifitegrast is slightly more effective than placebo in improving eye dryness, but 
not as safe based on the number of OAE. Lifitegrast can be considered a safe monotherapy for 
DED based on the efficacy of improving eye dryness and improbability of causing severe OAE. 
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INTRODUCTION 
Dry eye disease (DED) is a condition caused by inadequate quality or quantity of tear 
production necessary for lubrication of the eye surface which results in eye dryness, discomfort, 
irritation, burning, visual disturbances, and foreign body sensation. The ocular discomfort and 
impairment in visual acuity that occurs due to DED leads to a significant impact on quality of 
life. This condition can also be referred to as keratoconjunctivitis sicca, dysfunctional tear 
syndrome, and dry eye syndrome. Common risk factors include female gender, advancing age, 
hormonal alterations, systemic diseases, use of contact lenses, medications including 
antihistamines and anticholinergics, vitamin and nutritional deficiencies, ocular surgeries, and 
low environmental humidity. DED can also be associated with Sjogren’s syndrome, a chronic 
inflammatory condition affecting lacrimal and salivary gland functioning. 
The etiology of dry eyes is multifactorial and complex, resulting from a dysfunction in 
the interaction between the lacrimal glands, ocular surface, and the eyelids that leads to an 
inflammation of the ocular surface and hyperosmolarity of the tear film.1,2 The pathophysiology 
of DED can be classified as either an increased evaporative loss of tears or a decreased tear 
production. The increase in tear film evaporation often results from meibomian gland 
dysfunction, decreased blinking, or structural abnormalities of the eyelids.2 Decreased tear 
production occurs secondary to destruction or dysfunction of the lacrimal glands.2 Adequate tear 
production by the lacrimal glands and proper evaporation of the tear film is necessary for 
adequate visual acuity and cleansing of the eye surface. Any disruption in these two processes 
leading to inflammation of the eye surface or hyperosmolarity of the tear film causes an 
activation of sensory nerve fibers on the ocular surface resulting in the symptoms of eye 
irritation and discomfort.2 
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DED currently affects approximately 16.4 million people in the United States and is one 
of the most common reasons for ophthalmology visits.3,4 However, the evaluation and diagnosis 
of DED can also be performed in an outpatient primary care or emergency setting by physicians 
and physician assistants. The diagnosis is based on an evaluation of patient-reported symptoms 
and observation of the eyes on physical exam. On examination, notable findings include 
conjunctival injection, excess tearing, entropion or ectropion, blepharitis, reduction in blinking, 
and visual impairment on acuity testing. A referral to the ophthalmologist is recommended if the 
etiology of symptoms is unclear, there is no improvement or relief with treatment, or severe pain 
or vision loss occurs. 
The overall expenses for DED continues to rise annually and are based on the cost of 
frequent visits to healthcare providers, pharmacologic therapy, and non-pharmacologic therapy. 
Overall direct and indirect annual cost to the healthcare system in the United States was 
estimated at $55.4 billion, with a direct cost equivalent to $738 per person per year. 5 Cost to 
society is currently estimated at $11,000 per patient per year. 5 Aside from the financial burden 
for the treatment of symptoms, DED also accounts for lost productivity in terms of absence from 
work or working with discomfort or altered visual acuity.6   
The goal of treatment of DED is to increase or supplement production of tears, slow 
evaporation of tears, reduce the resorption of tears, and reduce the inflammation of the ocular 
surface.7 First line treatment includes artificial tear supplementation with ophthalmic gels, 
ointments, and solutions, and the use of environmental strategies of coping which include 
frequent blinking, minimal exposure to air condition and heat, and use of humidifiers. Other 
treatments include nutritional supplements, topical or systemic corticosteroids, topical 
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cyclosporine, and punctal plugs. These current treatments specifically target symptomatic relief 
from DED only. 
Lifitegrast 5.0% ophthalmic solution is a new topical eye drop formulation that targets 
the underlying ocular surface inflammation and damage that causes DED. It was recently FDA 
approved as an integrin antagonist that functions to decrease T cell-mediated inflammation. This 
method was proposed as a new treatment because it has a dual mechanism of treating the 
underlying pathophysiology and providing symptom relief, unlike the other current treatment 
options. Therefore, lifitegrast may provide better long-term symptom relief and be beneficial in 
patients refractory to the current treatments. 
OBJECTIVE 
The objective of this selective EBM review is to determine whether or not lifitegrast 
5.0% ophthalmic solution is effective in improving eye dryness and safe, in terms of ocular 
adverse effects, in adults 18 years or older with dry eye disease. 
METHODS 
The articles used for this systematic review were selected based on relevance to the 
clinical question and evaluation of patient-oriented outcomes. Articles were obtained through 
PubMed database using the keywords “Dry Eye Disease,” “Lifitegrast,” and “Dry Eyes.” The 
articles included were written in English and published in peer-reviewed journals between 2014-
2017. Articles were excluded if published before 2008, written in languages other than English, 
or evaluated outcomes that were not patient oriented.  
This review evaluates three primary double-blinded, randomized placebo-controlled trials 
(RCTs). All three trials evaluated the efficacy, based on improvement of eye dryness, and safety, 
based on ocular adverse effects, of lifitegrast 5.0% ophthalmic solution in comparison to  
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Table 1 - Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion Criteria Exclusion Criteria W/D Interventions 
Holland 
et al., 
20168 
RCT 711 18-
93 
≥18 years old with hx of 
DED plus all of the 
following: VA  ≥0.7 
logmin angle of res from visit 1,  
fluorescein staining 2+ in 
1+ region in  ≥ 1 eye, 
VASEDS 40+ b/l, 
conjunctival redness +1 in 
at least one eye, artificial 
tear use 30 days before 
screening, and  positive 
response (≥1 eye) 
meeting the following at 
visits 1 & 2: ICSS 0.5+ 
and unanesthetized 
Schirmer Tear Test 
between 1-10 mm. 
Immunocompetent 
individuals with 
secondary Sjögren’s 
syndrome not on systemic 
steroids.  
Pregnancy, hypersensitivity to 
product, previously in a 
lifitegrast trial, use of 
medication for blepharitis or 
meibomian gland disease 
during study, ocular infection 
30 days prior to screening, 
significant blood loss 56 days 
prior to screening, ocular 
conditions/chronic illnesses, 
immunodeficiency, ocular 
surgery in past 12 months, laser 
capsulotomy in past 6 months, 
alcohol/drug abuse, contact use 
during study, and DED 
secondary to scarring or 
destruction of conjunctival 
goblet cells. All other 
ophthalmic medications were 
prohibited during study. 
74 Lifitegrast 
5.0% 
ophthalmic 
solution BID 
(upon 
wakening 
and before 
bedtime) 
single drop 
each eye for 
84 days  
Sheppard 
et al., 
20149 
RCT 588 20-
91 
≥18 years old with hx of 
DED, artificial tear use 
within past 6 months, 
presence of conjunctival 
redness, corneal 
fluorescein staining 2+ 
(any field in any eye), 
unanesthetized Schirmer 
tear test between 1-
10mm, and VA ≥0.7 
logmin angle of res b/l.  
Contraindications or 
hypersensitivity to product, 
active ocular inflammation by 
slit-lamp exam, active ocular 
infection, ocular surgery in past 
12 months, contact use during 
study, and pregnancy. All other 
ophthalmic medications were 
prohibited during study.   
23 Lifitegrast 
5.0% 
ophthalmic 
solution 1 
drop per eye 
BID 
(morning 
and evening) 
for 84 day 
study period  
Tauber et 
al., 201510 
RCT 718 19-
97 
≥18 years old with hx of 
DED, artificial tear use in 
past 30 days, VA  ≥0.7 
logmin angle of res, fluorescein 
staining 2+ in ≥1 eye 
region, conjunctival 
redness 1+ in ≥1 eye, 
EDS ≥40, and positive 
response (≥1 eye) 
meeting the following at 
visits 1&2: ICSS ≥0.5 and 
unanesthetized Schirmer 
tear test between 1-
10mm. 
Immunocompetent 
individuals with 
secondary Sjögren’s 
syndrome not on systemic 
steroids.  
Pregnancy, contraindications or 
hypersensitivity to product, 
previous lifitegrast therapy, use 
of medication for blepharitis or 
meibomian gland disease, 
ocular infection within previous 
30 days, blood loss in previous 
56 days, ocular 
conditions/chronic illnesses, 
immunodeficiency, ocular 
surgery within previous 12 
months, laser capsulotomy in 
previous 6 months, 
alcohol/drug abuse, contact use 
during study, and DED 
secondary to scarring or 
destruction of conjunctival 
goblet cells. All other 
ophthalmic medications, 
antihistamines, and aspirin were 
prohibited during study.  
49 BID dosing 
of lifitegrast 
5.0% 
ophthalmic 
solution 
(morning 
and before 
bed), single 
drop each 
eye 
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placebo. The study population includes adults over the age of 18 with a history of dry eye 
disease. Statistics reported in the articles included mean change from baseline, NNH, RBI, ABI, 
and p-values. Table 1 displays the demographics & characteristics of the included studies. 
OUTCOMES MEASURED 
 All three RCTs measured the efficacy of lifitegrast in comparison to placebo using an eye 
dryness score (EDS). The EDS was obtained from a subject-reported assessment using a 7-item 
visual analog scale (VAS). The VAS was scored on a 0-100 scale with 0 referring to no 
discomfort and 100 referring to maximal discomfort.8,9,10 In all three studies, the 7 items included 
eye dryness, itching, burning/stinging, eye discomfort, foreign body sensation, pain, and 
photophobia. All studies also asked participants to subjectively rate each of these items on a 
horizontal scale from 0-100 with a single score for both eyes. This efficacy assessment was 
completed on day -14 (screening visit), 0, 14, 42, and 84. The primary efficacy point of the 
Holland and Tauber studies was the EDS obtained from the VAS. In the Sheppard study, the 
EDS obtained from the VAS was a supportive subjective efficacy end point. 
 The safety of lifitegrast compared to placebo was also measured throughout each of the 
three RCTs. Investigator safety assessments and recordings of adverse ocular effects were 
conducted at all study visits after the first dose of lifitegrast. The investigator of each study 
assessed the self-reported adverse ocular effects of the study drug and placebo for severity. The 
severity was rated as mild, moderate, or severe.  The most common ocular adverse events that 
were reported by participants included reduced visual acuity, instillation site irritation/burning, 
and instillation site reaction.8,9,10 This systematic review will focus on the results from day 84 of 
each of the trials.  
RESULTS 
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 The efficacy and safety of lifitegrast 5.0% ophthalmic solution in comparison to placebo 
was evaluated in all three RCTs. The study period for each of the trials was 12 weeks in duration. 
Majority of the participants in each of the trials were female and Caucasian. In all three RCTs, 
participants in the lifitegrast group received a single drop of lifitegrast 5.0% ophthalmic solution 
in each eye twice daily, once upon wakening and once before bedtime, for 84 days. Participants 
in the placebo group followed this same schedule with a matched placebo ophthalmic solution. 
At the beginning of each of the trials, participants were given a vial of the investigational product 
or placebo. Participants returned the vial at each visit for assessment of compliance with 
treatment.  In all RCTs, participants who discontinued the study were analyzed using the last 
observation carried forward. 
In the Holland et al. study, 711 participants between the ages of 18 to 93 with a history of 
DED were included in the study and randomized into the lifitegrast group (n=355) or the placebo 
group (n=365).8 Six hundred and thirty-seven participants completed the trial. Of the 
participants, 96.5% in the lifitegrast group and 97.6% in the placebo group were compliant with 
treatment. Participants were considered noncompliant if they took less than 20% or more than 
80% of the expected treatment doses between visits and were withdrawn from the study if this 
occurred twice.  
The mean change in baseline of the EDS on day 84 of the trial was approximately -37 for 
the lifitegrast group (54.2% reduction) and -30 for the placebo group (43.5% reduction). This 
resulted in a treatment effect of 7 which indicated that participants in the lifitegrast group had a 
7-point greater reduction (10.7%) in the EDS from baseline than the placebo group. The 
treatment effect was statistically significant, indicated by a p-value of 0.0007, and precise, with a 
narrow 95% CI of 3.04-11.28.8 Refer to Table 2 for the efficacy results of this study.  
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In the Holland et al. study, the number of overall ocular adverse effects in the lifitegrast 
group was greater than the placebo group, as shown in Table 3. Of the participants, 17.8% in the 
placebo group and 39.5% in the lifitegrast group reported ocular adverse effects ranging in 
severity of mild, moderate, or severe. Of the ocular adverse effects in the lifitegrast group, 31.7% 
were mild, 7.3% were moderate, and 0.6% were severe. According to the NNH, for every 5 
patients treated with lifitegrast, 1 additional person will have a mild, moderate, or severe ocular 
adverse effect. The safety results of this study are reported in Table 4.  
Table 2: Comparison of Efficacy of Lifitegrast vs Placebo based on the Mean Change from 
Baseline of the EDS 
 Mean Change from 
Baseline on day 84 
(Lifitegrast) 
Mean Change from 
Baseline on day 84 
(Placebo) 
Treatment Effect  
RCT Numerical Percent Numerical Percent Numerical Percent 95% 
CI 
P-value 
Holland et 
al.8 
-37 54.2% -30 43.5% 7 10.7% 3.04-
11.28 
0.0007 
Sheppard 
et al.9 
-15.2 37.8% -10.6 25.5% 4.6 12.3% - 0.0291 
Tauber et 
al.10 
-35.3 50.7% -22.75 32.9% 12.55 17.8% 8.51-
16.7 
<0.0001 
 
The Sheppard et al. study included 588 participants between the age of 20-91 years old 
with a history of DED. Five hundred and sixty-five participants completed the study. Participants 
were randomized into the placebo group (n=295) and the lifitegrast group (n=293).9 Th mean 
change from baseline on day 84 of the trial was -10.6 for placebo (25.5% reduction) and -15.2 
for lifitegrast (37.8% reduction). The treatment effect was 4.6, indicating a 4.6-point greater 
reduction (12.3%) in EDS with lifitegrast. The treatment effect was statistically significant based 
on the p-value of 0.0291.9 The efficacy results of this study are shown in Table 2. 
Lifitegrast was shown to cause more mild, moderate, and severe adverse ocular effects 
than placebo. Of the participants in the lifitegrast group, 63.5% developed ocular adverse effects, 
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in comparison to 26% in the placebo group, as shown in Table 3. Of the participants in the 
lifitegrast group who developed ocular adverse effects, 56% were mild, 7% moderate, and 0.5% 
severe. The calculated NNH indicated that 1 additional person will develop adverse ocular 
effects for every 3 treated with lifitegrast. The safety results of this study are shown in Table 4. 
Table 3: Percentage of Participants who Experienced Ocular Adverse Effects 
(Combination of Mild, Moderate, and Severe)  
RCT Lifitegrast Placebo 
Holland et al.8 39.5% 17.8% 
Sheppard et al.9 63.5% 26% 
Tauber et al.10 33.7% 16.4% 
 
In the Tauber et al. study, 718 subjects from the ages of 19 to 97 years old with a history 
of DED were analyzed. Participants were randomized into the placebo group (n=360) or the 
lifitegrast group (n=358).10 Forty nine of the total participants discontinued the study before day 
84. Of the participants, 95.5% in the placebo group and 93% in the lifitegrast group were 
compliant with treatment. Participants were considered noncompliant if greater than 20% of the 
expected dose was missed since the previous visit or greater than 120% of the expected dose was 
taken.  
The mean change from baseline on day 84 was -22.75 in the placebo group (32.9% 
reduction) and -35.3 in the lifitegrast group (50.7% reduction), resulting in a treatment effect of 
12.55. This indicates that participants in the lifitegrast group had a 12.55-point (17.8%) greater 
reduction from baseline in the EDS than those in the placebo group. The treatment effect was 
significant based on the p-value of <0.0001 and precise, based on the 95% CI of 8.51-16.70.9 
The efficacy results of this study are shown in Table 2.  
In terms of safety, lifitegrast caused mild, moderate, or severe adverse ocular effects in 
33.7% of participants in comparison to 16.4% in the placebo group, as shown in Table 3. Of the 
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ocular adverse effects that occurred in the lifitegrast group, 84% were mild, 8.6% were moderate, 
and 1.7% were severe. According to the NNH, for every 6 patients treated with lifitegrast, 1 
additional person will develop an adverse ocular effect. The safety results of this study are 
reported in Table 4.  
Table 4: Safety Analysis of Lifitegrast vs Placebo 
RCT Relative Risk 
Increase (RRI) 
Absolute Risk 
Increase (ARI) 
Number Needed to 
Harm (NNH) 
Holland et al.2 1.213 0.217 5 
Sheppard et al.8 1.44 0.375 3 
Tauber et al.7 1.055 0.173 6 
 
DISCUSSION 
Lifitegrast, also known by the brand name Xiidra, is a new treatment for the symptoms of 
dry eye disease that was approved by the FDA in July of 2016 for individuals 17 and older. 
There are currently no other indications for the use of this drug. Lifitegrast is an integrin 
antagonist that functions to decrease T-cell mediated inflammation, thought to cause DED.8,9,10 It 
is a 5.0% ophthalmic solution that comes in a single use container and currently costs around 
$600 per 30-day supply package in the United States. The current dosing regimen is 1 drop in 
each eye every 12 hours. Contact lens users are advised to remove the lenses before application 
of the solution and wait 15 minutes before reinsertion. Contraindications include hypersensitivity 
to lifitegrast or the drug formulation. The most common adverse effects noted include dysgeusia, 
irritation at the application site, and decreased visual acuity.8,9,10 
Lifitegrast was shown to be slightly more effective in treating eye dryness in compared to 
placebo. All three trials showed a small treatment effect based on the mean change from baseline 
of the EDS from the self-reported VAS. In each trial, the treatment effect was statistically 
significant based on the p-value. According to the NNH and the comparison of the percent of 
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individuals with ocular adverse effects between the study groups, lifitegrast was shown to be less 
safe than placebo. Although more participants in the lifitegrast group had ocular adverse effects 
and the value for the NNH was small in all studies, the ocular adverse effects were mild to 
moderate with very few cases being severe. In addition, the adverse effects were not unexpected, 
and the most common effects were irritation/burning and site reaction with application, which is 
common with any topical ophthalmic solution. The studies did not show any local or systemic 
infection from lifitegrast or any long-term effects that would impair quality of life. Based on this 
information, lifitegrast appears to be a generally safe treatment method. It can be concluded that 
lifitegrast is effective in treating eye dryness and is generally safe in individuals 18 and older 
with DED. 
Although each of the studies displayed that lifitegrast was effective in improving eye 
dryness in individuals with DED, there were limitations based on the populations specifically 
studied. Majority of participants in all three trials were Caucasian and female. This caused 
limitation in the generalizability of the treatment effect since different races and gender were not 
evaluated equally. Also, all three RCTs only included individuals actively or recently using 
artificial tear substitutes. The Holland and Tauber RCTs only included individuals with DED that 
had used artificial tears for symptomatic relief at least 30 days prior to the study and the 
Sheppard study only included those who used artificial tears in the past 6 months. Therefore, 
individuals who had discontinued use of artificial tears in the past and were not currently or 
recently using artificial tears were excluded from these RCTs. Reasoning for previous 
discontinuation of treatment may have been due to ineffective symptom relief from other 
methods. With the use of this criteria for participant selection, individuals with long term or 
advanced dry eye disease may have been excluded.  
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Other limitations were also based on the inclusion and exclusion criteria. The three RCTs 
prohibited contact lens use during the study period, therefore individuals who desired to use 
contact lenses were excluded. Consequently, the efficacy and safety of this drug cannot be 
applied to individuals with contact lenses based on these three RCTs. Participants were also 
prohibited from using additional therapy for DED with lifitegrast, including artificial tears or 
ophthalmic solutions, during the trial period. Therefore, the efficacy and safety of lifitegrast is 
only based on the sole use of lifitegrast as a monotherapy. The antagonistic or synergistic effects 
of lifitegrast with other treatment regimens cannot be predicted based on this systematic analysis 
of lifitegrast. All three of the trials included a 12-week duration of therapy with lifitegrast. This 
limited determination of the long-term effectiveness and safety of the use of lifitegrast for DED. 
CONLUSIONS 
 Lifitegrast 5.0% ophthalmic solution was slightly more effective, but not safer than 
placebo in all three RCTs evaluated in this systematic review. Based on the efficacy results for 
improving eye dryness and the low probability of severe ocular adverse effects, lifitegrast should 
be considered as a new monotherapy for the treatment of eye dryness in patients 18 and older 
with DED, especially those who fail other current treatment regimens. Future research studies 
should focus on a longer trial period with lifitegrast with more specific attention to the safety 
assessment. Research in populations with contact lenses should also be considered. Other future 
studies evaluating lifitegrast in combination with other treatment modalities for DED, including 
artificial tears, steroids, and other ophthalmic medications, are warranted to determine use of 
lifitegrast as an add on or combination medication. 
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